SFG
VNDA icon

SevenBridge Financial Group’s Vanda Pharmaceuticals VNDA Stock Holding History

SevenBridge Financial Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-275
Closed -$4K – 558
2019
Q2 		$4K Hold
275
– – ﹤0.01% 548
2019
Q1 		$5K Buy
+275
New +$6.27K ﹤0.01% 496

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SevenBridge Financial Group's VNDA Position: Q3 2019 in Review

SevenBridge Financial Group sold out of Vanda Pharmaceuticals (VNDA) in Q3 2019, closing a stake of 275 shares — an estimated $4K sold.

SevenBridge Financial Group first reported a position in VNDA in Q1 2019 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • SevenBridge Financial Group reported no remaining Vanda Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • SevenBridge Financial Group sold 275 Vanda Pharmaceuticals shares in Q3 2019, an estimated $4K.
  • SevenBridge Financial Group first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • SevenBridge Financial Group's Vanda Pharmaceuticals position peaked at $5K in Q1 2019.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on SevenBridge Financial Group's 13F filing for Q3 2019, filed 9 Oct 2019.